Ulcerative colitis
Conditions
Interventions
Randomized treatment with mesalazine suppository or oral mesalazine for 2 weeks
Switch from oral mesalazine to mesalazine suppository for 2 weeks
Sponsors
Saitama Medical Center, Saitama Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients, more than 18 years old with active rectal type of ulcerative colitis 2. Patients treated with oral mesalazine drugs less than 2.4g for more than 2 weeks 3. Patients with active ulcerative colitis whose bloody stool scores are more than 1 4. Male or female, inpatients or outpatients will be permitted to be entered
Exclusion criteria
Exclusion criteria: 1. Patients started to be treated with rectal 5-ASA and/or rectal steroids within 30 days before entry 2. Patients started to be treated with oral steroids within 14 days before entry 3. Patients with pregnancy or with the possibility of pregnancy 4. Patients with allergy of mesalazine and/or salicylic acid 5. Patients who have experienced severe side effects of mesalazine. 6. Patients with liver and/or renal dysfunctuon 7. Patinets with malignancy or with the history of malignancy 8. Patients induced in remission with biologics or cyteapheresis 9. Patients diagnosed not to be appropriate in entry by doctors
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Dissapearance rates of bloody stool on week 2 | — |
Countries
Japan
Contacts
Public ContactShingo Kato
Saitama Medical Center, Saitama Medical University Department of Gastroenterology and Hepatology
Outcome results
None listed